Atlas
143 compounds, with the numbers that matter.
Half-life, administration route, how long it takes to clear, what each compound is used for, and what to watch — for every peptide, GLP-1 agonist, SARM, androgen and ancillary in the Peptid AI library. Each entry links to its full guide.
BPC-157
Healing & recoveryBody Protection Compound — gut, tendon, and vascular repair. Most-studied healing peptide; popular starter compound.
4 h half-lifeSubcutaneousCJC-1295 with DAC
Performance & GHLong-acting GHRH analog via Drug Affinity Complex. Weekly dosing rationale, sleep and recovery tracking.
7.0 d half-lifeSubcutaneousGHK-Cu
Skin, hair & aestheticCopper peptide — skin, hair, and wound-healing. Measurements, photography, realistic timelines.
1 h half-lifeSubcutaneousInsulin (Human)
Other research compoundsMost dangerous compound on the menu — hypoglycemia risk is acute. Medical use only.
1 h half-lifeSubcutaneousIpamorelin
Performance & GHSelective growth-hormone secretagogue — clean profile, minimal cortisol/prolactin spike.
2 h half-lifeSubcutaneousMK-677
Performance & GHAn orally active ghrelin-mimetic growth hormone secretagogue (ibutamoren) that raises GH and IGF-1 pulses. It is not a SARM despite often being grouped with them.
1.0 d half-lifeOralOral Semaglutide
GLP-1 & weight lossA daily pill form of semaglutide, the same GLP-1 receptor agonist as the injectable, approved for chronic weight management and launched in January 2026. Absorption depends on strict fasted dosing.
7.0 d half-lifeOralOrforglipron
GLP-1 & weight lossOral small-molecule GLP-1 receptor agonist taken as a once-daily pill with no food or water timing restrictions. FDA-approved for chronic weight management in April 2026 under the brand Foundayo.
1.3 d half-lifeOralRetatrutide
GLP-1 & weight lossTriple-agonist (GLP-1 / GIP / glucagon). Strongest weight-loss in trials; titration + safety guidance.
6.0 d half-lifeSubcutaneousSemaglutide
GLP-1 & weight lossLong-acting GLP-1 agonist (Ozempic / Wegovy). Now also available as an oral 25 mg tablet approved for weight management (launched Jan 2026) — see the Oral Semaglutide entry.
6.9 d half-lifeSubcutaneousSermorelin
Performance & GHFull-length GHRH analog. Realistic expectations for sleep, recovery, and IGF-1 changes.
12 min half-lifeSubcutaneousSomatropin (HGH)
Performance & GHRecombinant human growth hormone. Requires serious safety + dose discipline; bloodwork-driven.
2.5 h half-lifeSubcutaneousTB-500
Healing & recoveryThymosin Beta-4 fragment — soft-tissue and tendon recovery. Long half-life relative to fragment size.
3 h half-lifeSubcutaneousTirzepatide
GLP-1 & weight lossDual GLP-1 / GIP agonist (Mounjaro / Zepbound). In Dec 2024 Zepbound also became the first drug FDA-approved for obstructive sleep apnea in adults with obesity.
5.0 d half-lifeSubcutaneousAHK-Cu
Skin, hair & aestheticCopper tripeptide focused on hair and scalp. Comparison with GHK-Cu; tracking hair/skin changes.
30 min half-lifeSubcutaneousAnastrozole
Ancillaries (SERMs / AIs)Non-steroidal aromatase inhibitor (Arimidex). Lowers estrogen on aromatizing androgen cycles.
1.9 d half-lifeOralAOD-9604
GLP-1 & weight lossModified HGH fragment — fat-loss focus, lipolytic. Failed obesity trials; protocol design implications.
1.5 h half-lifeSubcutaneousCabergoline
Ancillaries (SERMs / AIs)A long-acting dopamine agonist that lowers prolactin, used to manage hyperprolactinemia and related sexual dysfunction. High chronic doses carry a cardiac valve risk.
2.7 d half-lifeOralCagriSema
GLP-1 & weight lossA once-weekly fixed combination of the amylin analog cagrilintide and semaglutide delivering roughly 22.7% average body-weight loss in trials. It is not yet approved, with regulatory filing expected in late 2026.
7.0 d half-lifeSubcutaneousCardarine (GW-501516)
SARMsA PPAR-delta agonist (GW-501516) usually grouped with SARMs although it is not a true androgen modulator. It is best known for boosting endurance and fat oxidation.
1.0 d half-lifeOralCJC-1295 No-DAC (Mod GRF 1-29)
Performance & GHPulsatile GHRH (Mod GRF 1-29) — mimics natural growth-hormone pulses, daily dosing required.
30 min half-lifeSubcutaneousClenbuterol
Other research compoundsA long-acting beta-2 agonist used off-label as a thermogenic fat-loss agent. It raises metabolic rate but stresses the cardiovascular system.
1.5 d half-lifeOralClomiphene (Clomid)
Ancillaries (SERMs / AIs)Fertility SERM. Stimulates LH/FSH to restore endogenous testosterone and sperm production.
5.0 d half-lifeOralDulaglutide
GLP-1 & weight lossWeekly GLP-1 agonist (Trulicity). Clean titration ladder; tradeoff assessment vs newer compounds.
3.8 d half-lifeSubcutaneousEnclomiphene
Ancillaries (SERMs / AIs)The trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) used as a testosterone-replacement alternative. It raises endogenous testosterone while preserving fertility.
1.0 d half-lifeOralEpitalon
LongevityKhavinson tetrapeptide. Telomerase research; effects accumulate over cycles, short-protocol courses.
30 min half-lifeSubcutaneousGHRP-6
Performance & GHAppetite-forward GH secretagogue. Strong hunger response; useful for bulking-phase tracking.
18 min half-lifeSubcutaneousGlutathione
Other research compoundsMaster antioxidant — IV vs oral bioavailability is the central tracking question.
2 h half-lifeIntravenousHCG
Other research compoundsHuman chorionic gonadotropin. TRT support and fertility protocols; specific metrics for both contexts.
1.3 d half-lifeSubcutaneousHexarelin
Performance & GHStrongest older GHRP. Faster desensitization than newer compounds; short cycles required.
42 min half-lifeSubcutaneousHGH Fragment 176-191
Performance & GHHGH C-terminal fragment. Fat-loss focus without IGF stimulation; protocol structure with measurable markers.
1 h half-lifeSubcutaneousIGF-1 LR3
Performance & GHExtended-half-life IGF-1 analog. Hypoglycemia warning — careful protocol design + measurement required.
1.0 d half-lifeSubcutaneousKPV
Healing & recoveryAnti-inflammatory tripeptide. Logging framework across gut, skin, and inflammatory endpoints.
1 h half-lifeSubcutaneousLigandrol (LGD-4033)
SARMsA potent oral SARM (LGD-4033) valued for size and strength gains at low milligram doses. It reached early human trials for muscle wasting.
1.3 d half-lifeOralLiothyronine (T3)
Other research compoundsThe synthetic form of the active thyroid hormone T3, prescribed for hypothyroidism and used off-label to accelerate fat loss. Exogenous dosing suppresses natural thyroid output.
1.0 d half-lifeOralLiraglutide
GLP-1 & weight lossDaily GLP-1 agonist (Saxenda / Victoza). Daily-injection-class tradeoffs vs weekly compounds.
13 h half-lifeSubcutaneousMazdutide
GLP-1 & weight lossA once-weekly dual glucagon (GCG) and GLP-1 receptor agonist. It was approved in China in June 2025 for weight management but is not approved in the US or EU.
5.0 d half-lifeSubcutaneousMelanotan II
Skin, hair & aestheticTanning peptide. Loading + maintenance protocols, photos, realistic pigment timelines.
1 h half-lifeSubcutaneousMelatonin
Other research compoundsSleep hormone. Most people take 10x too much — precision dosing improves outcomes meaningfully.
42 min half-lifeOralMethandrostenolone (Dianabol)
Androgens & steroidsDianabol — classic oral bulker. Fast mass + water gain, heavy estrogenic and hepatic load.
4.5 h half-lifeOralMOTS-c
LongevityMitochondrial-encoded peptide. Real biology, modest human data; metabolic and exercise endpoints.
1 h half-lifeSubcutaneousNandrolone Decanoate
Androgens & steroidsDeca-Durabolin — long-ester nandrolone. Joint-comfort reputation, slow build, slow clear.
6.0 d half-lifeIntramuscularNicotinamide Riboside (NR)
LongevityNAD+ precursor with extensive supplementation evidence. Comparison with NMN; realistic outcomes.
1.5 h half-lifeOralNMN
LongevityNAD+ precursor — debated oral bioavailability. Focused on measurable human outcomes vs marketing.
30 min half-lifeOralOstarine (MK-2866)
SARMsThe mildest and most-studied selective androgen receptor modulator, known clinically as enobosarm (MK-2866). It was investigated as a treatment for muscle wasting.
1.0 d half-lifeOralOxandrolone (Anavar)
Androgens & steroidsAnavar — a "mild" oral DHT derivative. Liver-strain and lipid impact still real.
9 h half-lifeOralOxytocin
Other research compoundsSocial neuropeptide via intranasal route. Honest framing — literature limits + situational protocols.
6 min half-lifeIntranasalPT-141 (Bremelanotide)
Other research compoundsMelanocortin agonist — sexual response. On/off effect profile; common attribution errors to avoid.
2.7 h half-lifeSubcutaneousRAD-140 (Testolone)
SARMsA strong oral SARM (testolone) marketed for pronounced strength and lean mass gains. It was originally explored for muscle wasting and breast cancer.
20 h half-lifeOralRapamycin (Sirolimus)
LongevityAn approved mTOR-inhibiting immunosuppressant explored off-label for longevity using intermittent weekly dosing. Interest centers on its effects on cellular aging pathways.
2.5 d half-lifeOralSelank
Other research compoundsAnxiolytic heptapeptide. Solo framework separating signal from placebo; objective metrics matter.
30 min half-lifeIntranasalSemax
Other research compoundsACTH fragment for focus / cognition. Solo framework separating effects from caffeine and sleep.
30 min half-lifeIntranasalStanozolol (Winstrol)
Androgens & steroidsWinstrol — oral DHT derivative known for harsh lipid effects and joint dryness.
9 h half-lifeOralSustanon 250
Androgens & steroidsFour-ester testosterone blend — staggered release from propionate to decanoate.
IntramuscularTamoxifen
Ancillaries (SERMs / AIs)SERM (Nolvadex). Blocks estrogen at the breast + restarts the HPG axis in post-cycle protocols.
5.4 d half-lifeOralTesamorelin
Performance & GHGHRH analog — visceral-fat reduction. FDA-approved for HIV lipodystrophy. Protocol with measurable markers.
30 min half-lifeSubcutaneousTestosterone Cypionate
Androgens & steroidsLong-ester testosterone, near-identical to enanthate. Standard US TRT preparation.
5.0 d half-lifeIntramuscularTestosterone Enanthate
Androgens & steroidsLong-ester testosterone — the TRT and bulking backbone. Weekly injection, broad clinical history.
4.5 d half-lifeIntramuscularTestosterone Undecanoate
Androgens & steroidsA very long-ester testosterone used for TRT, available as the injectables Nebido and Aveed and the oral Jatenzo. Its long half-life allows dosing every several weeks.
20.0 d half-lifeIntramuscularTrenbolone Acetate
Androgens & steroidsFast-acting trenbolone — frequent injections, same potency and risk profile as the enanthate.
1.0 d half-lifeIntramuscularTrestolone (MENT)
Androgens & steroidsA potent injectable nandrolone-like androgen (7-alpha-methyl-19-nortestosterone) with strong anabolic activity. It is heavily suppressive and aromatizes to a potent estrogen.
7.0 d half-lifeIntramuscular5-Amino-1MQ
LongevityNNMT inhibitor — metabolic research. Limited human data; tracking framework for the available signals.
OralAndarine (S4)
SARMsAn early oral SARM (S4) known for a drier, harder look and strength gains. It was never approved and has largely been superseded by newer SARMs.
4 h half-lifeOralARA-290 (Cibinetide)
Other research compoundsTissue-protective peptide developed for small-fiber neuropathy. Pain + inflammation tracking.
2 h half-lifeSubcutaneousArgireline (Acetyl Hexapeptide-8)
Skin, hair & aestheticTopical "Botox-like" peptide — reduces expression-line depth by limiting muscle contraction signals.
TopicalBoldenone Undecylenate
Androgens & steroidsEquipoise (EQ) — very long ester, slow lean gains, raises red-blood-cell count.
14.0 d half-lifeIntramuscularBPC-157 / TB-500 blend
Healing & recoveryPre-mixed BPC-157 / TB-500 recovery stack — convenience versus dose-flexibility tradeoffs.
SubcutaneousCagrilintide
GLP-1 & weight lossLong-acting amylin analog. Now discussed mainly as half of CagriSema (with semaglutide) — REDEFINE data ~22.7% loss, filing expected late 2026.
6.6 d half-lifeSubcutaneousCalcitonin
Other research compoundsCalcium-regulating peptide. Bone and calcium-disorder clinical protocols with responsible tracking.
30 min half-lifeSubcutaneousCerebrolysin
Other research compoundsPorcine-brain peptide mixture — neurotrophic research, used clinically for stroke/dementia abroad.
IntramuscularCJC-1295 No-DAC + Ipamorelin blend
Performance & GHPre-mixed CJC-1295 No-DAC + Ipamorelin. Pre-mix vs separate-vial tracking implications.
SubcutaneousDihydroboldenone (DHB)
Androgens & steroidsAn injectable non-aromatizing anabolic steroid (1-testosterone) known for lean strength gains. It is notorious for severe post-injection pain.
2.0 d half-lifeIntramuscularDrostanolone Enanthate
Androgens & steroidsLong-ester Masteron — same DHT-derived compound, weekly dosing instead of EOD.
5.0 d half-lifeIntramuscularDrostanolone Propionate (Masteron)
Androgens & steroidsShort-ester Masteron — DHT-derived, valued for a dry/hard look in lean users.
20 h half-lifeIntramuscularDSIP
Other research compoundsDelta sleep-inducing peptide. Converts vague sleep impressions into measurable deep-sleep data.
12 min half-lifeSubcutaneousExemestane
Ancillaries (SERMs / AIs)Steroidal (suicidal) aromatase inhibitor (Aromasin). Irreversibly binds aromatase, gentler on lipids.
1.0 d half-lifeOralExenatide
GLP-1 & weight lossOriginal GLP-1 (Byetta / Bydureon) — Gila monster venom-derived. Twice-daily or weekly formulations.
2.4 h half-lifeSubcutaneousFinasteride / Dutasteride
Ancillaries (SERMs / AIs)Oral 5-alpha-reductase inhibitors that lower DHT to slow hair loss and treat benign prostatic hyperplasia (BPH). Finasteride is selective while dutasteride blocks more of the enzyme.
6 h half-lifeOralFisetin
LongevityA plant flavonoid studied as a senolytic — a compound that clears senescent cells — typically taken in short hit-and-run pulses. Most evidence to date is preclinical.
OralFluoxymesterone (Halotestin)
Androgens & steroidsA potent 17-alpha-alkylated oral androgen prized for raw strength and aggression rather than size. It carries a very high hepatotoxic burden.
9 h half-lifeOralGHRP-2
Performance & GHClassic ghrelin-mimetic GH secretagogue. Strong GH release; tracks alongside cortisol and prolactin.
18 min half-lifeSubcutaneousGLOW blend
Skin, hair & aestheticPre-mixed GHK-Cu / BPC-157 / TB-500. Proprietary blend — attribution challenges for outcomes.
SubcutaneousGonadorelin (GnRH)
Other research compoundsGnRH agonist — HPG-axis support during TRT, fertility maintenance. Pulsatile dosing.
6 min half-lifeSubcutaneousIGF-1 DES (1-3)
Performance & GHTruncated short-acting IGF-1 variant. Site-specific activity; bodybuilding research context.
18 min half-lifeSubcutaneousIpamorelin + CJC-1295
Performance & GHClassic GHRH + GHRP pairing. Comparison of paired GH-releasing peptides with protocol structure and tracking.
SubcutaneousKisspeptin-10
Other research compoundsUpstream HPG-axis signal. Reproductive-hormone research; logging focused on HPG endpoints.
30 min half-lifeSubcutaneousLetrozole
Ancillaries (SERMs / AIs)Potent non-steroidal aromatase inhibitor (Femara). Easy to over-suppress estrogen — small doses.
2.0 d half-lifeOralMatrixyl (Palmitoyl Pentapeptide-4)
Skin, hair & aestheticA topical collagen-signaling peptide (palmitoyl pentapeptide-4) widely used in anti-aging skincare. It aims to stimulate collagen for firmer, smoother skin.
TopicalMechano Growth Factor (MGF)
Performance & GHMuscle-damage-responsive IGF-1 splice variant. Very short half-life, post-workout timing critical.
6 min half-lifeSubcutaneousMelanotan I (Afamelanotide)
Skin, hair & aestheticSlower, cleaner MT cousin — slower onset. FDA-approved for erythropoietic protoporphyria.
1 h half-lifeSubcutaneousMesterolone (Proviron)
Androgens & steroidsAn oral DHT derivative that lowers SHBG and supports libido rather than driving large muscle gains. It is often used as an ancillary alongside other compounds.
12 h half-lifeOralMetformin
LongevityPrescription longevity drug. Tracking guide accounting for prescription status + GI side effects.
5 h half-lifeOralMethasterone (Superdrol)
Androgens & steroidsA 17-alpha-alkylated oral anabolic steroid (methyldrostanolone) known for rapid strength and mass gains. It is notably harsh on the liver and blood lipids.
8 h half-lifeOralMethenolone Enanthate (Primobolan)
Androgens & steroidsPrimobolan — a milder DHT-derived anabolic with a low-side-effect reputation. Still suppressive.
5.0 d half-lifeIntramuscularNA-Selank-Amidate
Other research compoundsN-acetyl, amidated Selank — more stable, longer-acting variant of the anxiolytic heptapeptide.
IntranasalNA-Semax-Amidate
Other research compoundsN-acetyl, amidated Semax — more stable, longer-acting variant of the ACTH-fragment nootropic.
IntranasalNAD+ Direct
LongevityDirect NAD+ — IV or subcutaneous. Tracking framework weighing cost vs evidence.
30 min half-lifeIntravenousNADH
LongevityReduced NAD+ form. Oral framework for fatigue, cognition, and Parkinson-disease contexts.
1 h half-lifeOralNandrolone Phenylpropionate
Androgens & steroidsNPP — short-ester nandrolone. Same compound as Deca, faster on and off.
2.7 d half-lifeIntramuscularNoopept
Other research compoundsSynthetic nootropic. Oral protocol; task-based cognitive metrics over subjective impressions.
30 min half-lifeOralOxymetholone (Anadrol)
Androgens & steroidsAnadrol — potent oral bulker. Large rapid mass gain with strong hepatic and blood-pressure load.
8.5 h half-lifeOralPEG-MGF
Performance & GHPEGylated MGF — much longer half-life than native MGF, weekly dosing schedule.
2.5 d half-lifeSubcutaneousRacetams
Other research compoundsA family of nootropics including piracetam, aniracetam and phenylpiracetam, used for cognition and focus. Potency and stimulation vary widely across the class.
5 h half-lifeOralRaloxifene
Ancillaries (SERMs / AIs)A breast-selective SERM used to treat and prevent gynecomastia and to protect bone density. It antagonizes estrogen in breast tissue while acting as an agonist in bone.
1.2 d half-lifeOralSalmon Calcitonin
Other research compoundsOlder clinical bone-density use. Bone-density and calcium-marker tracking framework.
1 h half-lifeIntranasalSelank + Semax
Other research compoundsTwo popular Russian nootropics. Objective metrics framework for paired nootropic protocols.
IntranasalSermorelin + Ipamorelin blend
Performance & GHPre-mixed Sermorelin + Ipamorelin (GHRH + GHRP). Practical for daily dosing; tradeoffs vs separates.
SubcutaneousSNAP-8 (Acetyl Octapeptide-3)
Skin, hair & aestheticA topical peptide (acetyl octapeptide-3) used in cosmetic serums as a needle-free Botox-mimetic. It aims to soften the look of expression lines at the skin surface.
TopicalSpermidine
LongevityA naturally occurring polyamine, available as a supplement, that induces autophagy — the cell's self-cleaning process. It is being studied for its links to healthy aging.
OralStenabolic (SR9009)
SARMsA REV-ERB agonist (stenabolic) often grouped with SARMs although it acts on circadian metabolism rather than androgen receptors. It has been studied mainly in rodents.
4 h half-lifeOralTB-500 + BPC-157 stack
Healing & recoveryDecision framework for stacking vs cycling BPC-157 and TB-500 separately. Tracking implications for both routes.
SubcutaneousTestosterone Propionate
Androgens & steroidsShort-ester testosterone — frequent injections, faster clearance, easier to stop.
20 h half-lifeIntramuscularThymosin Alpha-1
Other research compoundsApproved immune peptide (Zadaxin). Clinical history for hep B/C; protocol + tracking guidance.
2 h half-lifeSubcutaneousToremifene
Ancillaries (SERMs / AIs)A tamoxifen-like SERM used for estrogen control and gynecomastia management, with a generally cleaner lipid profile than tamoxifen. It also helps support endogenous testosterone.
5.4 d half-lifeOralTrenbolone Enanthate
Androgens & steroidsLong-ester trenbolone — extremely potent, high side-effect burden. Not a beginner compound.
5.0 d half-lifeIntramuscularTriptorelin
Other research compoundsGnRH agonist with clinical uses including post-cycle HPG restoration. Off-label restart tracking.
7 h half-lifeSubcutaneousTurinabol
Androgens & steroidsOral Turinabol — milder, non-estrogenic, steady lean gains. Still 17aa and suppressive.
16 h half-lifeOralUrolithin A
LongevityA gut-derived metabolite, sold as Mitopure, that promotes mitophagy — the recycling of damaged mitochondria. Human trials report gains in muscle endurance.
1.0 d half-lifeOralWolverine blend
Healing & recoveryBranded BPC-157 / TB-500 pre-mix — same compounds, naming convention only. Flexibility loss for convenience.
SubcutaneousYK-11
SARMsA synthetic steroidal compound marketed as a SARM that is also claimed to inhibit myostatin. Human data are minimal and it is poorly characterized.
12 h half-lifeOralAmycretin
GLP-1 & weight lossAn investigational GLP-1 and amylin receptor agonist being developed in both oral and subcutaneous forms. It entered Phase 3 development in 2026 and is not approved.
7.0 d half-lifeSubcutaneousB7-33
Other research compoundsSingle-chain relaxin analog. Fibrosis and cardiac research; limited human data.
SubcutaneousBimagrumab
GLP-1 & weight lossAn investigational anti-activin type II receptor monoclonal antibody given by infusion that adds skeletal muscle while reducing fat mass. It is being studied alongside GLP-1 therapies and is not approved.
10.0 d half-lifeIntravenousDihexa
Other research compoundsPreclinical angiotensin-derived nootropic — synaptogenesis research. Essentially no human data.
OralDNP (2,4-Dinitrophenol)
Other research compoundsA mitochondrial uncoupler that forces the body to burn energy as heat, producing dramatic fat loss. It is extremely dangerous, with a narrow margin between an effective dose and a lethal one.
1.0 d half-lifeOralFollistatin / ACE-031
Performance & GHExperimental myostatin inhibitors — follistatin-based agents and ACE-031, a soluble activin receptor — aimed at removing the brake on muscle growth. Human use is investigational.
SubcutaneousGLP-2 TZ (Teduglutide)
Other research compoundsApproved GLP-2 analog (teduglutide) — short bowel syndrome. Gut-focused tracking framework.
2 h half-lifeSubcutaneousHumanin
LongevityMitochondrial-DNA-encoded peptide. Early-stage neuroprotection / metabolic research.
SubcutaneousL-Carnitine
Other research compoundsEnergy + fat oxidation. Oral, injectable, and IV protocols with realistic expectations.
SubcutaneousLL-37
Healing & recoveryCathelicidin antimicrobial peptide. Limited human data; framework focuses on infection and inflammation markers.
SubcutaneousP21
Other research compoundsCNTF-derived speculative research peptide. Minimal human evidence; honest tracking if used experimentally.
SubcutaneousPE-22-28
Other research compoundsSpadin-derived TREK-1 blocker — research-stage antidepressant peptide. Animal data only.
SubcutaneousPemvidutide
GLP-1 & weight lossAn investigational once-weekly GLP-1 and glucagon receptor dual agonist designed to spare lean mass during weight loss. It is not yet approved.
5.0 d half-lifeSubcutaneousPinealon
LongevityShort Khavinson peptide. Cognitive and stress tracking; realistic expectations for short courses.
SubcutaneousSS-31 (Elamipretide)
LongevityCardiolipin-binding tetrapeptide. Mitochondrial-disease research; clinical-trial markers.
2.5 h half-lifeSubcutaneousSurvodutide
GLP-1 & weight lossAn investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It has shown promising liver-fibrosis and weight data in trials.
7.0 d half-lifeSubcutaneousThymalin
Other research compoundsImmune peptide. Older-population thymic-function studies; cycle tracking framework.
SubcutaneousThymosin Beta-4
Healing & recoveryFull-length parent molecule of TB-500. Broader anti-inflammatory and immune profile than the fragment.
1.0 d half-lifeSubcutaneousThyrotropin-Releasing Hormone (TRH)
Other research compoundsHypothalamic tripeptide. Thyroid and prolactin axis research; clinical context tracking.
6 min half-lifeSubcutaneousTirzepatide vs Semaglutide
GLP-1 & weight lossComparison guide — pick incretin by side-effect tolerance and tracking needs.
Vasopressin (AVP / ADH)
Other research compoundsPituitary hormone (AVP / ADH). Water retention + memory research; clinical-use framing.
12 min half-lifeSubcutaneousVilon
LongevityKhavinson dipeptide. Immune and longevity research; older-population focus.
SubcutaneousVK2735
GLP-1 & weight lossAn investigational GIP and GLP-1 receptor dual agonist in oral and subcutaneous forms, currently in Phase 3 trials. It is not approved for any use.
4.2 d half-lifeSubcutaneous
Full index by class
GLP-1 & weight loss (18)
Healing & recovery (8)
Performance & GH (19)
- CJC-1295 with DAC
- Ipamorelin
- MK-677
- Sermorelin
- Somatropin (HGH)
- CJC-1295 No-DAC (Mod GRF 1-29)
- GHRP-6
- Hexarelin
- HGH Fragment 176-191
- IGF-1 LR3
- Tesamorelin
- CJC-1295 No-DAC + Ipamorelin blend
- GHRP-2
- IGF-1 DES (1-3)
- Ipamorelin + CJC-1295
- Mechano Growth Factor (MGF)
- PEG-MGF
- Sermorelin + Ipamorelin blend
- Follistatin / ACE-031
Longevity (16)
Skin, hair & aesthetic (8)
Androgens & steroids (23)
- Methandrostenolone (Dianabol)
- Nandrolone Decanoate
- Oxandrolone (Anavar)
- Stanozolol (Winstrol)
- Sustanon 250
- Testosterone Cypionate
- Testosterone Enanthate
- Testosterone Undecanoate
- Trenbolone Acetate
- Trestolone (MENT)
- Boldenone Undecylenate
- Dihydroboldenone (DHB)
- Drostanolone Enanthate
- Drostanolone Propionate (Masteron)
- Fluoxymesterone (Halotestin)
- Mesterolone (Proviron)
- Methasterone (Superdrol)
- Methenolone Enanthate (Primobolan)
- Nandrolone Phenylpropionate
- Oxymetholone (Anadrol)
- Testosterone Propionate
- Trenbolone Enanthate
- Turinabol
SARMs (7)
Ancillaries (SERMs / AIs) (10)
Other research compounds (34)
- Insulin (Human)
- Clenbuterol
- Glutathione
- HCG
- Liothyronine (T3)
- Melatonin
- Oxytocin
- PT-141 (Bremelanotide)
- Selank
- Semax
- ARA-290 (Cibinetide)
- Calcitonin
- Cerebrolysin
- DSIP
- Gonadorelin (GnRH)
- Kisspeptin-10
- NA-Selank-Amidate
- NA-Semax-Amidate
- Noopept
- Racetams
- Salmon Calcitonin
- Selank + Semax
- Thymosin Alpha-1
- Triptorelin
- B7-33
- Dihexa
- DNP (2,4-Dinitrophenol)
- GLP-2 TZ (Teduglutide)
- L-Carnitine
- P21
- PE-22-28
- Thymalin
- Thyrotropin-Releasing Hormone (TRH)
- Vasopressin (AVP / ADH)
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.